Page results
-
Introduction of Bordetella pertussis PCR testing at Halo laboratory (Health Services Laboratories)
-
Patients with COVID-19 will be given the cystic fibrosis drug ‘Dornase alfa’ to determine if it can help improve survival by reducing excess inflammation in the lungs in a trial at UCLH.
-
Neurological complications of COVID-19 can include delirium, brain inflammation, stroke and nerve damage, finds a new UCL and UCLH-led study.
-
UCLH will be part of a major UK research study looking at the long-term health impacts of COVID-19.
-
SUMMIT Study results on the benefits of large-scale screening for lung cancer are published in The Lancet Oncology today (26 March), ahead of the formal addition of lung cancer screening to the UK national screening programme from 1 April.
-
The North Central London Integrated Care System (NCL ICS) has new services and staff training to support patients with inherited red cell disorders, including Sickle Cell and Thalassaemia, living in Barnet, Camden, Enfield, Haringey and Islington.
-
This page provides details of your treatment pathway coordinator for the Teenage and Young Adult Cancer Service.
-
Dr. Patrick Murphy is a principal clinical neuropsychologist at the National Hospital for Neurology and Neurosurgery
-
The North Central London Integrated Care System (NCL ICS) has new services and staff training to support patients with inherited red cell disorders, including Sickle Cell and Thalassaemia, living in Barnet, Camden, Enfield, Haringey and Islington.
-
The video-assisted stroke triage project, developed by the UCLH stroke service in partnership London Ambulance Service (LAS) has won the HSJ Patient Safety Award for Clinical Governance & Risk Management in Patient Safety.
File results
-
FOI/2022/0550 - Patients that have been treated for glioblastoma brain cancer
-
FOI/2022/0553 - Patients tested for non-small cell lung cancer biomarkers
-
FOI/2022/0561 - Regulation (EU) 2016/425 Declarations of Conformity for all type IIR surgical masks provided as PPE to staff
-
FOI/2022/0571 - Treatment for biologic medicines in Dermatology
-
FOI/2022/0572 - Treatments for Hidradenitis Suppurativa and Psoriasis
-
FOI/2022/0573 - Use of WhatsApp by or within the Trust
-
FOI/2022/0513 - Myelofibrosis treatment
-
FOI/2022/0540 - Electronic patient record
-
FOI/2022/0541 - Serious Incidents Level 2 deaths/ serious harm
-
FOI/2022/0576 - Medications within dermatology